KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EPS (Weighted Average and Diluted) (2018 - 2025)

Historic EPS (Weighted Average and Diluted) for CRISPR Therapeutics AG (CRSP) over the last 8 years, with Q4 2025 value amounting to -$1.35.

  • CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) fell 22142.86% to -$1.35 in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.5, marking a year-over-year decrease of 4942.53%. This contributed to the annual value of -$6.47 for FY2025, which is 4907.83% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported EPS (Weighted Average and Diluted) of -$1.35 as of Q4 2025, which was down 22142.86% from -$1.17 recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year EPS (Weighted Average and Diluted) high stood at $9.44 for Q2 2021, and its period low was -$2.4 during Q2 2022.
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$0.83, with a median of -$1.42 in 2023.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 82615.38% in 2021, then crashed by 22142.86% in 2025.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) stood at -$1.74 in 2021, then grew by 19.54% to -$1.4 in 2022, then soared by 180.71% to $1.13 in 2023, then crashed by 137.17% to -$0.42 in 2024, then crashed by 221.43% to -$1.35 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$1.35 in Q4 2025, compared to -$1.17 in Q3 2025 and -$2.4 in Q2 2025.